NORMED 5 TABLET

PROGEN 100 TABLET
November 9, 2017
NORVEL 72 TABLET
November 9, 2017
NORMED 5 TABLET Norethisterone 5mg Tablet
Composition : Each un-coated tablet contains Norethisterone 5mg.
Indications : Metropathia haemorrhagica, Premenstrual syndrome, Postponement of menstruation, Dysmenorrhoea, Endometriosis, Menorrhagia, Disseminated Carcinoma of the breast.
Contraindications :  It is contraindicated in patients with known hypersensitivity to the active substances or to any of the excipients.
Adverse Effects : Drowsiness, headache, nausea, lower abdominal pain, fatigue, thrombo-embolic disorders, increased blood pressure, pulmonary embolism, retinal thrombosis, thrombophlebitis, cholestatic liver changes, disturbed liver function.
Dosage : Metropathia haemorrhagica (dysfunctional uterine bleeding): 1 tablet 3 times daily for 10 days. Bleeding is arrested usually within 1-3 days. A withdrawal bleeding resembling normal menstruation occurs within 2-4 days after discontinuing treatment.
Prophylaxis against recurrence of dysfunctional bleeding: If there are no signs of resumption of normal ovarian function (no rise of morning temperature in the second half of the cycle), recurrence must be anticipated. Cyclical bleeding can be established with 1 tablet twice daily from the 19th to the 26th day of the cycle.
Premenstrual syndrome (including premenstrual mastalgia): Premenstrual symptoms such as headache, migraine, breast discomfort, water retention, tachycardia and psychic disturbances may be relieved by the administration of 2-3 tablets daily from the 19th to the 26th day of the cycle. Treatment should be repeated for several cycles. When treatment is stopped, the patient may remain symptom-free for a number of months.
Postponement of menstruation: In cases of too frequent menstrual bleeding, and in special circumstances (eg operations, travel, sports) Dosage: 1 tablet three times daily, starting 3 days before the expected onset of menstruation. A normal period should occur 2-3 days after the patient has stopped taking tablets.
Dysmenorrhoea: functional or primary dysmenorrhoea is almost invariably relieved by the suppression of ovulation. 1 tablet three times daily for 20 days, starting on the fifth day of the cycle (the first day of menstruation counting as day 1). Treatment should be maintained for three to four cycles followed by treatment-free cycles. A further course of therapy may be employed if symptoms return.
Endometriosis (pseudo-pregnancy therapy): long-term treatment is commenced on the 5th day of the cycle with 2 tablets daily for the first few weeks. In the event of spotting, the dosage is increased to 4 and, if necessary, 5 tablets daily.
After bleeding has ceased, the initial dose is usually sufficient. Duration of treatment: 4-6 months continuously, or longer if necessary.
Menorrhagia (hypermenorrhoea): 1 tablet 2-3 times a day from the 19th to the 26th day of the cycle (counting the first day of menstruation as day 1).
Disseminated Carcinoma: of the breast the starting dose is 8 tablets per day increasing to 12 tablets after 6 weeks if no regression is noted and may be continued indefinitely. If no remission is obtained within 9 weeks of treatment none should be expected.